Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (9012)	3/9/1999 5:28:00 PM
From: Cacaito	Respond to of 17367

Bluegreen, there is not tacit approval from DSMB. But there is the pro-drug bias, the research benefit on the placebo group, and the tyranny of the <0.05 standard for statistical significance. 1. Pro-drug bias: every DSMB member wants a drug that works. This is a positive bias for approval and they know it, so they look for more stringent numbers. 2. Placebo benefit, the protocols are strict top of the line care, not the standard of care. This benefit the placebo patient. Some Statistical scientists have try to devise ways to determine a measurable value of this. 3.Others want the tyranny of <0.05 change to 0.1 (a new tyranny for the bluegreens of the earth ,sorry could not resist, g. If the DSMB members are looking at the numbers, they see 0.07 and no safety issue they will allow it to continue to see if more numbers will prove the efficacy or to see if the trend goes toward 0.05. 4. My respects and admiration for the Yankee Clipper, Joe DiMaggio